Biotechnology Training Courses at the National Institutes of Health
BIO-TRAC home contact


Building 10
Room 1N241 -
MSC 1115
Bethesda, MD



TRAC 54: Making Cardiomyocytes from iPSCs

Often late stage clinical trials are terminated due to cardiotoxicity. There is great need to develop proper screens that are predictive of human clinical response to medications. This course will cover numerous applications using cardiomyocytes. The lectures will cover cardiac development and cardiac diseases which provides the necessary background for this course in appreciating how stem cells can be differentiated from iPSCs and be used to develop disease in a dish models as well as screens to monitor specific cardiac phenotypes such as arrhythmia and cardiac toxicity. Lectures will also cover the methodology to drive differentiation of iPSCs toward cardiac lineages and the development of cardiac reporter lines that will be useful for screening applications.

The laboratory exercises will include basic handling of cardiomyocytes and then delve into discovery techniques that focus on disease modeling and phenotypic screening for small molecule therapeutics. Lab exercises will conclude with providing exposure to transfection techniques as well as assays for proarrhythmia and toxicity.

Cardiac Development and Disease; iPS and ESC: Methodology for Differentiation of Cardiomyoctyes from ESC and iPSC ; iPS and ESC: Overview on Benefits and Limitations of iPSC/ESC-derived Cardiomyocytes; Characterisation and Validation of hESC Derived Cardiomyocytes; High Content Screening for Cardiotoxicity of Anti-Cancer Drugs in hESC Derived Cardiomyocytes; Bioenergetic Modulation of Kinase Inhibitor Cardiotoxicity in hESC Derived Cardiomyocytes; Cardiac angiogenesis and vascular biology; Cardiac Physiology; Cardiac Electrophysiology and Functional Assays; Functional Improvement Following Cell Therapy for Ischemic Myocardium.

Laboratory Topics:
Cardiac differentiation from iPSCs ; Basic Handling: Thawing and Plating iPSC-derived Cardiomyoctyes; Discovery Techniques; MEA Demonstration; xCelligance Demonstration; PART I (Transfecting iCell Cardiomyoctyes with one or a Combination of the Following: (a) Fluorescent Protein Marker and Subsequent Analysis via Flow for Transfection Efficiency, Luciferase Reporter, Most Likely CRE-Luciferase and Then Induction and Read-out of the System, (c) siRNA to Knock Down Housekeeping Gene and then Quantify Via Flow or HCl or Knock Down Ion Channels and Provide a Functional Readout); Compound dose response curves; Transfection and reporter assays; Organelle Toxicity; Discovery Techniques PART II: Disease Modeling and Phenotypic Screening for Small Molecule Therapeutics (Hypertrophy With Protein Based HCl Readout and a Phenotypic Screen with 6 Compounds to Look for Amelioration of the Pathology); Reporter Assays; GE Cytell DemonstratioN: Imaging (GE Lab); Organelle Toxicity; Field Trip to NCATS, Lecture on High Content Screening Methods

Benefits for Early Registering:

Trac 54
June 16-20, 2014
Monday - Friday

9:00 - 5:00 p.m.

35 lecture/lab contact hours
Early Registration: $995 (by 5/09/14); $1,095
(Lecture & Hands-on Laboratory)
  home · courses · calendar · registration · specialty programs · contact

Biotechnology Training Courses at the National Institutes of Health
Sponsored by the Foundation for Advanced Education in the Sciences